# lisa_legal_aspects
Source: /mnt/g/My Drive/_Knowledge/_PBM/6.PBM_Bibliothèque/Selection for Knowledge Base/Copy of 2025_06_02_PBM_Legal aspects_v1.pdf
Pages: 10
Extracted: {'title': 'Copy of 2025_06_02_PBM_Legal aspects_v1', 'author': 'N/A', 'subject': 'N/A', 'creator': 'N/A', 'producer': 'Skia/PDF m140 Google Docs Renderer', 'pages': 10}

================================================================================



--- Page 1 ---

PBM  Legal  aspects  
_Vielight/International/Europe/Lux/Fr/D
 
 
I'll  research  the  current  legal  and  regulatory  landscape  for  brain  photobiomodulation  devices  
across
 
these
 
key
 
regions.
 
This
 
is
 
a
 
rapidly
 
evolving
 
area
 
with
 
significant
 
regulatory
 
variations.Based
 
on
 
my
 
research
 
into
 
the
 
current
 
regulatory
 
landscape,
 
I'll
 
provide
 
you
 
with
 
a
 
comprehensive
 
analysis
 
of
 
the
 
legal
 
aspects
 
of
 
brain
 
photobiomodulation
 
across
 
the
 
regions
 
you
 
specified.
 
International/United  States  (FDA)  
Current  FDA  Classification  Framework:  Photobiomodulation  (PBM)  devices  are  regulated  
as
 
Class
 
II
 
medical
 
devices
 
under
 
21
 
CFR
 
878.4810,
 
878.4850,
 
878.5400,
 
and
 
890.5500.
 
However,
 
the
 
regulatory
 
landscape
 
is
 
complex
 
and
 
depends
 
on
 
intended
 
use.
 
Key  Legal  Categories:  
1.  Medical  Devices  (Class  II):  Devices  requiring  510(k)  premarket  notification  for  
medical
 
applications
 
such
 
as
 
aesthetics
 
and
 
dermatology
 
 2.  General  Wellness  Devices:  Light-emitting  products  intended  for  general  wellness  
use
 
that
 
present
 
low
 
risk
 
to
 
users
 
may
 
fall
 
under
 
the
 
FDA's
 
general
 
wellness
 
device
 
policy
 
rather
 
than
 
requiring
 
medical
 
device
 
regulation
 
 
Specific  Status  of  Vielight  Devices:  Vielight  devices  are  not  FDA-approved  for  any  
medical
 
indications,
 
though
 
the
 
company
 
is
 
ISO13485
 
certified
 
and
 
has
 
Health
 
Canada
 
approval
 
for
 
COVID-19
 
recovery.
 
This
 
means
 
they
 
operate
 
under
 
the
 
wellness
 
device
 
framework
 
in
 
the
 
US
 
market.
 
FDA  Guidance  Developments:  The  FDA  published  draft  guidance  in  2023  specifically  for  
PBM
 
devices,
 
with
 
final
 
guidance
 
expected
 
to
 
provide
 
clearer
 
regulatory
 
pathways.
 
European  Union  (MDR/CE  Marking)  
Regulatory  Framework:  Medical  devices  in  the  EU  require  CE  marking  demonstrating  
compliance
 
with
 
the
 
Medical
 
Device
 
Regulation
 
(MDR)
 
2017/745.
 
The
 
classification
 
depends
 
on
 
risk
 
assessment
 
and
 
intended
 
use.
 
Classification  Considerations:  
●  Class  I  (Low  Risk):  Self-certification  possible  for  lowest  risk  devices  

--- Page 2 ---

●  Class  IIa/IIb:  Requires  notified  body  assessment  ●  Class  III:  Highest  risk,  most  stringent  requirements  
Recent  Regulatory  Changes:  The  European  Commission  published  Implementing  
Regulation
 
2022/2347,
 
reclassifying
 
certain
 
brain
 
stimulation
 
equipment
 
without
 
medical
 
intended
 
use
 
as
 
Class
 
III
 
devices.
 
This
 
significantly
 
impacts
 
non-medical
 
brain
 
photobiomodulation
 
devices.
 
CE  Marking  Process:  Requires  quality  management  system  (ISO  13485),  technical  
documentation,
 
and
 
for
 
most
 
classes,
 
notified
 
body
 
assessment.
 
Luxembourg  
National  Implementation:  Medical  devices  must  be  registered  with  the  Health  Directorate  
before
 
market
 
placement,
 
with
 
registration
 
taking
 
4-6
 
weeks
 
for
 
Class
 
I
 
devices.
 
Regulatory  Authority:  The  Pharmacy  and  Medication  Department  under  the  Ministry  of  
Health
 
oversees
 
medical
 
device
 
regulation,
 
following
 
EU
 
MDR
 
requirements.
 
Registration  Requirements:  Manufacturers  must  register  devices  with  the  Health  
Directorate
 
and
 
may
 
require
 
authorized
 
representatives
 
in
 
the
 
EU.
 
Local  Context:  Neurofeedback  Luxembourg  operates  photobiomodulation  services,  
indicating
 
established
 
practice
 
within
 
the
 
wellness/non-medical
 
framework.
 
France  
National  Authority:  The  French  Agency  for  the  Safety  of  Medicines  and  Health  Products  
(ANSM)
 
ensures
 
compliance
 
with
 
medical
 
device
 
regulations
 
at
 
the
 
national
 
level.
 
Legal  Framework:  France  follows  EU  MDR  requirements  with  additional  national  oversight  
through
 
DGCCRF
 
for
 
medical
 
devices.
 
Liability  Considerations:  The  New  Product  Liability  Directive  (EU)  2024/2853  amends  
liability
 
rules
 
for
 
medical
 
devices,
 
including
 
those
 
using
 
AI
 
and
 
digital
 
technologies.
 
Germany  
Regulatory  Approach:  Germany  follows  a  self-assessment  system  for  medical  device  
advertising
 
rather
 
than
 
requiring
 
pre-approval
 
licenses.
 
Legal  Framework:  Medical  devices  are  regulated  under  EU  MDR  with  additional  German  
laws
 
including
 
the
 
Heilmittelwerbegesetz
 
(HWG)
 
for
 
advertising.
 
National  Implementation:  The  BfArM  (Federal  Institute  for  Drugs  and  Medical  Devices)  
oversees
 
medical
 
device
 
regulations,
 
implementing
 
EU
 
requirements
 
through
 
the
 
Medizinprodukterecht-Durchführungsgesetz
 
(MPDG).
 

--- Page 3 ---

Critical  Legal  Distinctions  
Medical  vs.  Wellness  Classification:  The  key  legal  differentiation  globally  depends  on:  
1.  Intended  Use:  Medical  claims  vs.  general  wellness  promotion  2.  Risk  Assessment:  Safety  profile  and  potential  hazards  3.  Marketing  Claims:  Specific  medical  conditions  vs.  general  wellbeing  
Practical  Recommendations  for  Your  Practice:  
1.  For  Medical  Applications:  Ensure  devices  have  appropriate  CE  marking  and  
medical
 
device
 
registration
 2.  For  Wellness  Applications:  Verify  claims  comply  with  general  wellness  policies  3.  Documentation:  Maintain  clear  intended  use  statements  and  avoid  medical  claims  
for
 
wellness-classified
 
devices
 4.  Professional  Liability:  Consider  professional  indemnity  insurance  covering  
photobiomodulation
 
therapy
 5.  Continuing  Education:  Stay  updated  on  evolving  regulations,  particularly  the  
emerging
 
EU
 
requirements
 
for
 
brain
 
stimulation
 
devices
 
Key  Compliance  Considerations:  
●  Vielight  devices  currently  operate  under  wellness  frameworks  rather  than  medical  
device
 
approval
 ●  Recent  EU  regulatory  changes  significantly  impact  brain  stimulation  devices  without  
medical
 
intended
 
use
 ●  Professional  practice  may  require  different  standards  than  device  classification  ●  National  implementations  of  EU  law  may  vary  in  enforcement  and  interpretation  
This  regulatory  landscape  is  rapidly  evolving,  particularly  for  brain  photobiomodulation  
devices,
 
with
 
increased
 
scrutiny
 
from
 
regulators
 
worldwide.
 
I
 
recommend
 
consulting
 
with
 
regulatory
 
affairs
 
specialists
 
for
 
specific
 
device
 
approvals
 
and
 
maintaining
 
awareness
 
of
 
ongoing
 
regulatory
 
developments.
 
 
I'll  search  for  more  specific  information  about  Vielight's  regulatory  status  and  practical  use  in  
Europe.Based
 
on
 
my
 
detailed
 
research,
 
here's
 
the
 
current
 
legal
 
status
 
for
 
using
 
Vielight
 
devices
 
in
 
Europe,
 
Luxembourg,
 
France,
 
and
 
Germany:
 
Vielight's  Current  European  Legal  Status  
Good  News:  Vielight  Devices  Appear  Unaffected  by  Recent  EU  Restrictions  
Vielight  devices  are  CE  certified  and  "compliant  with  the  European  CE  requirements  for  
safety"
 
and
 
"have
 
been
 
tested
 
for
 
electrical
 
safety
 
and
 
rendered
 
safe
 
by
 
TUV
 
Rheinland
 
standards".
 
Vielight
 
recently
 
received
 
CE
 
certification,
 
opening
 
up
 
the
 
European
 
market.
 

--- Page 4 ---

Key  Legal  Distinction:  
The  critical  regulatory  change  that  has  impacted  brain  stimulation  devices  in  Europe  
specifically
 
targets
 
equipment
 
intended
 
for
 
brain
 
stimulation
 
that
 
applies
 
"electrical
 
currents
 
or
 
magnetic
 
or
 
electromagnetic
 
fields
 
that
 
penetrate
 
the
 
cranium
 
to
 
modify
 
neuronal
 
activity
 
in
 
the
 
brain".
 
Vielight  devices  use  photobiomodulation  (light  energy),  NOT  electrical  currents  or  
magnetic
 
fields.
 
Brain
 
photobiomodulation
 
utilizes
 
"red
 
to
 
near-infrared
 
(NIR)
 
photons
 
to
 
stimulate
 
the
 
cytochrome
 
c
 
oxidase
 
enzyme"
 
rather
 
than
 
electrical
 
stimulation.
 
Practical  Implications  by  Region  
European  Union  (General)  
●  Legal  Status :  CE  marked  devices,  likely  classified  under  general  wellness/low-risk  
medical
 
devices
 ●  Usage :  Legal  for  practitioners  and  consumers  ●  Restrictions :  Devices  are  "not  yet  approved  by  any  national  regulatory  body  for  the  
treatment
 
of
 
medical
 
conditions
 
and
 
are
 
presently
 
only
 
for
 
the
 
enhancement
 
of
 
general
 
wellness
 
and
 
mental
 
acuity"
 
Luxembourg  
●  Regulatory  Framework :  Follows  EU  MDR  requirements  ●  Practical  Use :  Neurofeedback  Luxembourg  already  operates  photobiomodulation  
services,
 
indicating
 
established
 
practice
 ●  Professional  Use :  Legal  for  wellness  and  performance  enhancement  applications  
France  
●  National  Oversight :  ANSM  regulates  medical  devices  ●  Legal  Status :  CE  marked  devices  can  be  used  under  wellness  framework  ●  Professional  Liability :  Ensure  appropriate  professional  insurance  coverage  
Germany  
●  Regulatory  Approach :  Self-assessment  system  for  medical  device  use  ●  Distribution :  German  distributors  already  market  Vielight  devices  with  CE  marking  ●  Usage :  Legal  for  both  professional  and  consumer  use  
Important  Legal  Considerations  
What  You  CAN  Do:  
1.  Use  for  Wellness/Performance  Enhancement :  Mental  clarity,  cognitive  
performance,
 
stress
 
reduction
 

--- Page 5 ---

2.  Professional  Practice :  Integrate  into  neurofeedback,  coaching,  or  wellness  services  3.  Research  Applications :  Use  for  cognitive  enhancement  studies  
What  You  CANNOT  Do:  
1.  Medical  Claims :  Avoid  claiming  treatment  of  specific  medical  conditions  2.  Therapeutic  Marketing :  Don't  advertise  as  medical  treatment  without  appropriate  
medical
 
device
 
approval
 3.  Insurance  Billing :  Cannot  bill  medical  insurance  for  non-approved  medical  
indications
 
Compliance  Recommendations:  
1.  Documentation :  
 ○  Verify  CE  marking  on  devices  ○  Maintain  clear  intended  use  statements  (wellness,  not  medical)  ○  Keep  usage  protocols  within  wellness  framework  2.  Professional  Practice :  
 ○  Ensure  professional  liability  insurance  covers  photobiomodulation  ○  Provide  clear  informed  consent  about  wellness  vs.  medical  use  ○  Stay  within  scope  of  practice  3.  Marketing/Communications :  
 ○  Use  wellness/performance  language  rather  than  medical  terminology  ○  Reference  published  research  while  avoiding  therapeutic  claims  ○  Clearly  distinguish  from  medical  treatment  
Shipping  and  Distribution  
Users  report  successful  delivery  to  Europe,  though  shipping  costs  can  be  significant  (e.g.,  
$150
 
to
 
Belgium).
 
European
 
distributors
 
are
 
available
 
to
 
avoid
 
import
 
costs
 
and
 
ensure
 
proper
 
electrical
 
compatibility.
 
Bottom  Line  
Vielight  devices  are  currently  legal  to  use  in  Europe,  Luxembourg,  France,  and  
Germany
 
under
 
their
 
CE
 
marking
 
for
 
wellness/performance
 
enhancement
 
applications.
 
The
 
recent
 
EU
 
regulatory
 
changes
 
specifically
 
target
 
electrical
 
and
 
magnetic
 
brain
 
stimulation
 
devices,
 
not
 
light-based
 
photobiomodulation
 
devices
 
like
 
Vielight.
 
Key  Success  Factor :  Maintaining  clear  positioning  as  wellness/cognitive  enhancement  
tools
 
rather
 
than
 
medical
 
devices,
 
while
 
ensuring
 
appropriate
 
professional
 
standards
 
and
 
informed
 
consent
 
processes.
 

--- Page 6 ---

The  regulatory  landscape  remains  dynamic,  so  continued  monitoring  of  regulatory  
developments
 
is
 
advisable,
 
particularly
 
regarding
 
any
 
future
 
expansion
 
of
 
brain
 
stimulation
 
regulations
 
to
 
include
 
photobiomodulation
 
technologies.
 
 
Vielight_website_user  guides_documentation  etc:   
https://www.vielight.com/devices/?srsltid=AfmBOoqmc-HBoduZWjXv6kowrBZfFKHndSTp-wr
w37swEepVSFSCJP5G
 

--- Page 7 ---

What  do  I  risk  if  I  want  to  use  Vielight  for  
Alzheimer’s
 
disease
 
?
 
 
I'll  search  for  specific  information  about  the  legal  risks  and  regulatory  status  of  using  Vielight  
devices
 
for
 
Alzheimer's
 
disease
 
treatment.Based
 
on
 
my
 
research,
 
using
 
Vielight
 
devices
 
specifically
 
for
 
Alzheimer's
 
disease
 
treatment
 
presents
 
significant
 
legal
 
risks
 
that
 
you
 
should
 
carefully
 
consider.
 
Here's
 
a
 
comprehensive
 
analysis:
 
Current  Regulatory  Status  for  Alzheimer's  
Critical  Legal  Reality:  Vielight  devices  "were  not  labeled  for  treating  dementia  or  AD  and  
would
 
be
 
described
 
as
 
non-regulated,
 
'low
 
risk
 
general
 
wellness
 
products'".
 
The
 
company
 
states
 
their
 
device
 
will
 
be
 
"indicated
 
for
 
Alzheimer
 
patients
 
with
 
moderate
 
to
 
severe
 
impairment"
 
only
 
"subject
 
to
 
regulatory
 
clearance"
 
-
 
which
 
has
 
not
 
yet
 
been
 
obtained.
 
Current  Trial  Status:  Vielight  is  conducting  a  Phase  3  pivotal  Alzheimer's  trial  with  228  
participants
 
to
 
evaluate
 
efficacy
 
for
 
FDA
 
approval,
 
but
 
this
 
approval
 
does
 
not
 
yet
 
exist.
 
Specific  Legal  Risks  You  Face  
1.  Practicing  Medicine  Without  Appropriate  Authorization  
Risk  Level:  HIGH  
Using  devices  to  diagnose,  prevent,  treat,  or  cure  diseases  falls  under  the  broad  legal  
definition
 
of
 
"practicing
 
medicine,"
 
which
 
courts
 
interpret
 
broadly.
 
Using
 
a
 
wellness
 
device
 
specifically
 
for
 
Alzheimer's
 
treatment
 
could
 
constitute
 
unauthorized
 
medical
 
practice.
 
Consequences:  
●  Professional  licensing  board  investigations  ●  Civil  liability  for  unauthorized  medical  practice  ●  Criminal  charges  in  severe  cases  ●  Loss  of  professional  credentials  
2.  Professional  Liability  Exposure  
Risk  Level:  HIGH  
Professional  liability  increases  significantly  when  using  unapproved  treatments,  especially  
for
 
vulnerable
 
populations
 
like
 
elderly
 
patients
 
with
 
dementia.
 
Specific  Concerns:  
●  No  established  standard  of  care  for  photobiomodulation  in  Alzheimer's  ●  Informed  consent  challenges  with  cognitively  impaired  patients  

--- Page 8 ---

●  Lack  of  regulatory  safety  data  for  this  specific  use  ●  Devices  without  FDA  approval  have  reduced  ability  to  defend  against  tort  claims  
alleging
 
products
 
liability,
 
negligence,
 
or
 
breach
 
of
 
warranty
 
3.  Regulatory  Violations  
Risk  Level:  MODERATE  to  HIGH  
The  FDA  actively  monitors  and  takes  enforcement  action  against  entities  making  Alzheimer's  
treatment
 
claims
 
with
 
unapproved
 
products,
 
having
 
issued
 
"more
 
than
 
40
 
warning
 
letters
 
in
 
the
 
past
 
5
 
years".
 
Potential  Actions:  
●  FDA  warning  letters  ●  Cease  and  desist  orders  ●  Civil  penalties  ●  Criminal  prosecution  for  continued  violations  
4.  Insurance  and  Liability  Issues  
Risk  Level:  MODERATE  
●  Professional  liability  insurance  may  not  cover  treatment  with  non-approved  
devices
 
for
 
medical
 
conditions
 ●  Exclusions  likely  exist  for  experimental  or  unapproved  treatments  ●  Malpractice  insurance  typically  does  not  cover  costs  of  criminal  defense  
5.  Patient  Safety  and  Informed  Consent  Risks  
Risk  Level:  HIGH  
Legal  doctrine  requires  disclosure  of  "material  risks"  -  those  that  impact  a  patient's  decision  
to
 
undergo
 
treatment.
 
For
 
Alzheimer's
 
patients:
 
●  Capacity  to  consent  may  be  compromised  ●  Family/caregiver  consent  adds  complexity  ●  Experimental  nature  must  be  clearly  disclosed  ●  Alternative  approved  treatments  must  be  discussed  
Specific  European  Considerations  
Professional  Responsibility  Framework  
European  healthcare  systems  emphasize  professional  responsibility  and  evidence-based  
care.
 
Using
 
non-approved
 
devices
 
for
 
medical
 
conditions
 
could
 
trigger:
 
●  Professional  regulatory  board  investigations  

--- Page 9 ---

●  Medical  negligence  claims  under  national  tort  law  ●  Violations  of  professional  codes  of  conduct  
Patient  Rights  Legislation  
EU  patient  rights  directives  require:  
●  Clear  information  about  treatment  options  ●  Evidence-based  care  standards  ●  Informed  consent  documentation  
Risk  Mitigation  Strategies  (If  You  Proceed)  
1.  Legal  Framework  Compliance  
●  Obtain  legal  counsel  specializing  in  medical  device  law  ●  Verify  professional  liability  insurance  covers  experimental  treatments  ●  Document  extensively  that  this  is  investigational,  not  standard  care  
2.  Enhanced  Informed  Consent  Process  
●  Written  informed  consent  specifying  experimental  nature  ●  Guardian/POA  involvement  for  cognitively  impaired  patients  ●  Documentation  of  treatment  alternatives  discussion  ●  Second  medical  opinion  requirement  
3.  Professional  Protocol  
●  Medical  supervision  by  qualified  physician  ●  Baseline  and  follow-up  assessments  using  validated  scales  ●  Adverse  event  monitoring  and  reporting  protocols  ●  Limited  patient  population  (research  participants  only)  
4.  Documentation  Requirements  
●  IRB/Ethics  committee  approval  if  possible  ●  Patient  registry  for  safety  monitoring  ●  Clear  treatment  protocols  and  stopping  rules  ●  Regular  legal  compliance  reviews  
Bottom  Line  Legal  Assessment  
Using  Vielight  devices  specifically  for  Alzheimer's  treatment  currently  presents  HIGH  
legal
 
risk
 
because:
 
1.  No  regulatory  approval  exists  for  this  indication  2.  Crosses  from  wellness  into  medical  treatment  territory  

--- Page 10 ---

3.  Vulnerable  patient  population  increases  liability  exposure  4.  Limited  legal  defenses  available  for  unapproved  treatments  5.  Active  regulatory  enforcement  in  this  area  
Recommended  Approach  
Safest  Legal  Path:  
1.  Wait  for  regulatory  approval  from  ongoing  clinical  trials  2.  Refer  patients  to  clinical  trials  if  appropriate  3.  Use  devices  only  for  wellness/cognitive  enhancement  in  healthy  individuals  4.  Maintain  clear  wellness  boundaries  in  practice  and  documentation  
If  You  Must  Proceed:  
1.  Obtain  specialized  legal  counsel  immediately  2.  Secure  appropriate  insurance  coverage  3.  Implement  robust  informed  consent  protocols  4.  Consider  research/investigational  framework  only  5.  Limit  to  very  specific,  well-documented  cases  
The  legal  landscape  strongly  favors  waiting  for  proper  regulatory  approval  rather  than  risking  
significant
 
professional
 
and
 
legal
 
consequences
 
by
 
using
 
wellness
 
devices
 
for
 
medical
 
treatment
 
of
 
serious
 
neurodegenerative
 
conditions.
 
 